Evaluation of a surrogate virus neutralization test for high-throughput serosurveillance of SARS-CoV-2

Joachim Mariën, Johan Michiels, Leo Heyndrickx, Antoine Nkuba-Ndaye, Ann Ceulemans, Koen Bartholomeeusen, Joule Madinga, Placide Mbala-Kingebeni, Veerle Vanlerberghe, Steve Ahuka-Mundeke, Lin-Fa Wang, Kevin K Ariën

Research output: Contribution to journalA1: Web of Science-article

Abstract

High-throughput serological tests that can detect neutralizing antibodies against SARS-CoV-2 are desirable for serosurveillance and vaccine efficacy evaluation. Although the conventional neutralization test (cVNT) remains the gold standard to confirm the presence of neutralizing antibodies in sera, the test is too labour-intensive for massive screening programs and less reproducible as live virus and cell culture is involved. Here, we performed an independent evaluation of a commercially available surrogate virus neutralization test (sVNT, GenScript cPass™) that can be done without biosafety level 3 containment in less than 2 h. When using the cVNT and a Luminex multiplex immunoassay (MIA) as reference, the sVNT obtained a sensitivity of 94 % (CI 90-96 %) on a panel of 317 immune sera that were obtained from hospitalized and mild COVID-19 cases from Belgium and a sensitivity of 88 % (CI 81-93 %) on a panel of 184 healthcare workers from the Democratic Republic of Congo. We also found strong antibody titer correlations (r s>0.8) among the different techniques used. In conclusion, our evaluation suggests that the sVNT could be a powerful tool to monitor/detect neutralising antibodies in cohort and population studies. The technique could be especially useful for vaccine evaluation studies in sub-Saharan Africa where the basic infrastructure to perform cVNTs is lacking.

Original languageEnglish
Article number114228
JournalJournal of Virological Methods
Volume297
ISSN0166-0934
DOIs
Publication statusPublished - 2021

Cite this